Physician profile
Jacob Brems
NPI 1215381462
$4,728.75
in general payments reported to CMS, 2019-2025
25 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $702 · 2021: $1,427 · 2022: $490 · 2023: $1,021 · 2024: $514 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,767.68 | 2019-2023 | |
| Coloplast Corp | $746.11 | 2020-2023 | Speedicath |
| Procept Biorobotics Corporation | $275.93 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Sumitomo Pharma America, INC. | $271.68 | 2023-2024 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $228.34 | 2022-2024 | Erleada, Akeega |
| Bioprotect Medical, INC. | $205.98 | 2024-2025 | Bioprotect Balloon Implant System |
| Antares Pharma, INC. | $159.46 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Axonics, INC. | $157.68 | 2022-2023 | Axonics |
| Endo Pharmaceuticals INC. | $136.32 | 2021-2024 | Xiaflex |
| Astellas Pharma US INC | $125.27 | 2022-2024 | Myrbetriq |
| Pfizer INC. | $99.77 | 2023-2024 | |
| Blue Earth Diagnostics | $90.69 | 2022-2024 | |
| Urogen Pharma, INC. | $67.99 | 2023-2024 | Jelmyto |
| Tempus Ai, INC | $60.00 | 2024 | Xt Cdx |
| Hollister Incorporated | $48.63 | 2023 | Infyna Chic, Vapro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.94 | 2024 | Keytruda, Welireg |
| Ferring Pharmaceuticals INC. | $42.27 | 2024 | Adstiladrin |
| Accord Healthcare, INC. | $38.51 | 2023-2024 | |
| Halozyme INC | $36.78 | 2023 | |
| Progenics Pharmaceuticals, INC. | $26.22 | 2023 | Pylarify |
| Abbvie INC. | $24.30 | 2023 | Botox |
| Abc Home Medical Supply, INC. | $22.74 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $21.70 | 2022 | |
| Urovant Sciences INC | $15.11 | 2022 | |
| Myriad Genetic Laboratories, INC. | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Brems listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.